milrinone has been researched along with Atrial Fibrillation in 5 studies
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 7.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery." | 6.73 | Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008) |
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 3.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery." | 2.73 | Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008) |
| "Milrinone was administered intravenously in successive doses of 25, 50, and 75 micrograms/kg." | 2.66 | Milrinone in the treatment of chronic cardiac failure: a controlled trial. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1985) |
| "Bacteremia was the most common type of infection." | 1.43 | Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. ( Acharya, D; Hashim, T; Loyaga-Rendon, RY; Morgan, CJ; Pamboukian, SV; Revilla-Martinez, M; Sanam, K; Tallaj, JA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harhash, AA | 1 |
| Cassuto, J | 1 |
| Hussein, A | 1 |
| Achu, E | 1 |
| Zucker, MJ | 1 |
| Goldschmidt, M | 1 |
| Alpert, JS | 1 |
| Baran, DA | 1 |
| Acharya, D | 1 |
| Sanam, K | 1 |
| Revilla-Martinez, M | 1 |
| Hashim, T | 1 |
| Morgan, CJ | 1 |
| Pamboukian, SV | 1 |
| Loyaga-Rendon, RY | 1 |
| Tallaj, JA | 1 |
| Fleming, GA | 1 |
| Murray, KT | 1 |
| Yu, C | 1 |
| Byrne, JG | 1 |
| Greelish, JP | 1 |
| Petracek, MR | 1 |
| Hoff, SJ | 1 |
| Ball, SK | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Feneck, RO | 1 |
| Likoff, MJ | 1 |
| Weber, KT | 1 |
| Andrews, V | 1 |
| Janicki, JS | 1 |
| Wilson, H | 1 |
| Rocci, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RAAS, Inflammation, and Post-operative AF[NCT00141778] | Phase 2/Phase 3 | 455 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 0.7 |
| Spironolactone | 0.7 |
The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 1.4 |
| Ramipril | 2.0 |
| Spironolactone | 0 |
Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 11.6 |
| Ramipril | 13.8 |
| Spironolactone | 6.8 |
Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 10.6 |
| Spironolactone | 10.2 |
(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge
| Intervention | days (Mean) |
|---|---|
| Placebo | 6.8 |
| Ramipril | 5.7 |
| Spironolactone | 5.8 |
The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 27.2 |
| Ramipril | 27.8 |
| Spironolactone | 25.9 |
Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 2.7 |
| Ramipril | 1.3 |
| Spironolactone | 2.0 |
It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 1091.3 |
| Ramipril | 970.1 |
| Spironolactone | 576.4 |
C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ug/mL (Mean) | ||||
|---|---|---|---|---|---|
| Initiation of surgery | Postoperative day 1 | Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | |
| Placebo | 4.1 | 51.4 | 134.8 | 128.3 | 94.1 |
| Ramipril | 4.3 | 49.9 | 131.0 | 164.8 | 105.2 |
| Spironolactone | 3.9 | 64.3 | 127.8 | 189.4 | 126.5 |
Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 4.7 | 12.0 | 15.6 | 130.0 | 119.0 | 100.3 |
| Ramipril | 4.6 | 20.5 | 28.8 | 202.1 | 171.0 | 95.5 |
| Spironolactone | 6.6 | 11.3 | 17.4 | 145.7 | 164.9 | 109.6 |
Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 19.6 | 19.2 | 21.0 | 36.4 | 55.2 | 28.1 |
| Ramipril | 16.2 | 19.7 | 22.0 | 38.9 | 47.9 | 25.7 |
| Spironolactone | 17.3 | 17.3 | 20.1 | 34.0 | 48.9 | 31.0 |
3 trials available for milrinone and Atrial Fibrillation
| Article | Year |
|---|---|
Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery.
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Disease; | 2008 |
Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Blood Pressure; Cardiac Output; Cardiac Surgica | 1992 |
Milrinone in the treatment of chronic cardiac failure: a controlled trial.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Cardiomyopathy, Dilated; Chronic Disease; Clinical | 1985 |
2 other studies available for milrinone and Atrial Fibrillation
| Article | Year |
|---|---|
Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias.
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Defibrillators, Implantable; Dose-Response Relationsh | 2020 |
Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy.
Topics: Administration, Intravenous; Adult; Aged; Alabama; Atrial Fibrillation; Bacteremia; Cardiotonic Agen | 2016 |